The driver mutations typically observed in most NSCLC, such as tumor protein p53 (TP53), Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) translocations, are rarely present. This evidence concerns the gene TP53 and non-small cell lung carcinoma.